In a phase II randomized study of 275 patients in the adjuvant setting, a DC vaccine targeting the E75 peptide derived from the HER2 protein was tested with trastuzumab in breast cancer patients with low HER2 expression65. Here, ERBB2 is linked to breast carcinoma.